Topic: How To Invest

What do you think of Afexa Life Sciences, makers of Cold-fX? With people taking more precautions due to H1N1, this immune system booster seems to be selling very well. Would you recommend this stock? Best regards.

Article Excerpt

Afexa Life Sciences, $0.75, symbol FXA on Toronto (Shares outstanding: 104.9 million; Market cap: $78.7 million), changed its name from CV Technologies in April 2009. The company identifies and extracts the active ingredients found in some plants and uses them in its line of natural health products. Afexa has developed a system that involves isolating a target compound, then purifying it. This creates the chemical and pharmacological profiles that Afexa needs to seek patent protection and recognition from regulatory agencies. The company then puts the compound through clinical trials to determine dosages and uses. Cold-fX is the company’s lead product. Afexa says that its studies of Cold-fX, and special peer-reviewed laboratory studies, show that Cold-fX reduces the frequency, severity and duration of cold and flu symptoms. Cold-fX is extracted from ginseng, and has been on the market for several years. A number of celebrities endorse Cold-fX, including hockey stars and Olympic athletes. Besides Cold-fx, Afexa’s products include Remember-fX, to improve memory,…